Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

Study summary

The goal of this clinical research study is to study the safety of giving larger daily doses of proton radiation therapy than the standard dose levels given to treat lung cancer. Researchers want to find the highest daily dose of proton radiation that can be given without having to stop therapy due to side effects.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedProton Therapy

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 2, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?M.D. Anderson Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: M.D. Anderson Cancer Center
Interventions being studied: Radiation: Proton Therapy

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→

Treatment approach

Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Histologically or cytologically documented NSCLC, SCLC, thymic tumors, or carcinoid tumors 2. Patients not receiving concurrent chemotherapy 3. Patients that are eligible for concurrent treatment with biologic agents (epidermal growth factor receptor \[EGFR\] or vascular endothelial growth factor \[VEGF\] inhibitors) will be eligible for the study.

Reasons someone may not be able to joinExclusion criteria

1. Prior radiotherapy to the chest 2. Life expectancy \<6 months 3. Pregnancy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Texas MD Anderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 2, 2020. Always confirm current availability with the study team.

View original record ↗